Several studies presented recently at the American Heart Association's scientific sessions indicated that both gender and ethnic inequalities exist in the treatment and control of high cholesterol. One of the studies showed that at least 22.3% of all participants had cholesterol levels that met the guidelines for medication. Men were treated less often for low-density lipoprotein cholesterol levels and were less apt to keep them under control, compared with women.
Similar results were seen among African Americans and Hispanics. These groups were less likely to have their cholesterol levels treated and controlled, compared with Caucasians.
Get to know RESPIMAT, the slow-moving mist inhaler from Boehringer Ingelheim Pharmaceuticals, Inc.
Watch the RESPIMAT video and test your knowledge with a short multiple-choice quiz. When you get all the answers right, you’ll receive a certificate naming you a RESPIMAT T.O.P. Performer. Why not check it out today?
Clinical features with downloadable PDFs